Skip to main content

RedHill Biopharma Ltd. (RDHL)

NASDAQ: RDHL · Delayed Price · USD
4.86
-0.08 (-1.62%)
After-hours:Sep 23, 2021 7:25 PM EDT
4.94
0.19 (4.00%)
At close: Sep 23, 4:00 PM
Market Cap221.92M
Revenue (ttm)84.48M
Net Income (ttm)-94.95M
Shares Out46.72M
EPS (ttm)-2.31
PE Ration/a
Forward PE1,428.57
Dividendn/a
Ex-Dividend Daten/a
Volume739,575
Open4.73
Previous Close4.75
Day's Range4.71 - 4.98
52-Week Range4.48 - 11.52
Beta1.40
AnalystsStrong Buy
Price Target18.79 (+280.3%)
Est. Earnings DateNov 11, 2021

About RDHL

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infectio...

IndustryPharmaceuticals
Founded2009
CEODror Ben-Asher
Employees182
Stock ExchangeNASDAQ
Ticker SymbolRDHL
Full Company Profile

Financial Performance

In 2020, RDHL's revenue was $64.36 million, an increase of 923.03% compared to the previous year's $6.29 million. Losses were -$76.17 million, 80.1% more than in 2019.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for RDHL stock is "Strong Buy." The 12-month stock price forecast is 18.79, which is an increase of 280.28% from the latest price.

Price Target
$18.79
(280.28% upside)
Analyst Consensus: Strong Buy

News

RedHill Settles Movantik Patent Litigation With Aurobindo

RedHill Biopharma Ltd (NASDAQ: RDHL) has announced a settlement and license agreement with Aurobindo Pharma USA Inc resolving their patent litigation in the U.S. The litigation was related to Aurobindo'...

18 hours ago - Benzinga

RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Aurobindo

TEL AVIV, Israel and RALEIGH, N.C., Sept. 23, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.

22 hours ago - PRNewsWire

RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study

RedHill (RDHL) posts preliminary top-line data from a phase II/III study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Stocks falls as the study fails to achieve its goal.

1 week ago - Zacks Investment Research

Why RedHill Biopharma Stock Is Getting Crushed Today

A clinical failure is sending shareholders to the exits this morning.

1 week ago - The Motley Fool

What's Happening With RedHill Biopharma's Stock On Tuesday?

RedHill Biopharma Ltd (NASDAQ: RDHL) announced preliminary top-line data from Phase 2/3 study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Read Next:   RedHill Biopharma ...

1 week ago - Benzinga

RedHill Biopharma Reports Top-Line Data from Opaganib Phase 2/3 Study in Severe COVID-19 Patients

TEL AVIV, Israel and RALEIGH, NC, Sept. 14, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.

1 week ago - PRNewsWire

RedHill Biopharma To Test Its Oral Antiviral In COVID-19 Patients In South Africa

Regulatory authorities in South Africa have signed off RedHill Biopharma Ltd's (NASDAQ: RDHL) Phase 2/3 study evaluating RHB-107 (upamostat) for non-hospitalized patients with symptomatic COVID-19.  The...

1 week ago - Benzinga

RHB-107 P2/3 COVID-19 Study South Africa Approval

RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients with South African Approval The South African Health Products Regulatory Autho...

1 week ago - Accesswire

RedHill Biopharma Accelerates Ongoing U.S. Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Pa...

The South African Health Products Regulatory Authority (SAHPRA) has approved the Phase 2/3 study of once-daily orally-administered RHB-107 (upamostat) for patients with symptomatic COVID-19 who do not r...

1 week ago - PRNewsWire

RedHill's (RDHL) Opaganib Effective Against Kidney Fibrosis

Opaganib, Redhill's (RDHL) candidate for COVID-19, achieves a significant reduction in kidney fibrosis in preclinical studies.

2 weeks ago - Zacks Investment Research

RedHill Unveils New Movantik Data For Opioid-Induced Constipation

RedHill Biopharma Ltd (NASDAQ: RDHL) has announced new Movantik (naloxegol) Phase 3 study data analyses. The three analyses included pooled data from two Phase 3 studies involving 891 treated patients a...

2 weeks ago - Benzinga

RedHill Biopharma's Opaganib Demonstrates Significant Decrease of Kidney Fibrosis

COVID-19 and long COVID patients are at increased risk of developing kidney damage - Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model - Renal fibrosis is a progressive pro...

2 weeks ago - Accesswire

RedHill Biopharma Ltd Announces New Movantik Analyses at PAINWeek

RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021 Two new analyses of Movantik® (naloxegol) data evaluated the safety and efficacy of Movantik in a subgroup of patients age...

2 weeks ago - Accesswire

RedHill Biopharma Presents Three New Analyses of Movantik Data at PAINWeek 2021

TEL AVIV, Israel and RALEIGH, N.C., Sept. 7, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.

2 weeks ago - PRNewsWire

RedHill to Present at HCW & Cantor Conferences

RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences TEL AVIV, ISRAEL and RALEIGH, NC / ACCESSWIRE / September 2, 2021 / RedHill Biopharma Ltd.

3 weeks ago - Accesswire

RedHill Biopharma to Present at H.C. Wainwright Annual Global Investment and Cantor Global Healthcare Conferences

TEL AVIV, Israel and RALEIGH, NC, Sept. 2, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.

3 weeks ago - PRNewsWire

Why RedHill Biopharma Stock Jumped on Tuesday

An analyst on Wall Street thinks the company's commercial and development pipeline has been underestimated.

3 weeks ago - The Motley Fool

Cantor Sees 'Compelling Investment Opportunity' In This Biopharma

Cantor Fitzgerald has initiated coverage of RedHill Biopharma Ltd (NASDAQ:RDHL) with an Overweight rating and a $22 price target, an upside of approximately 115%. Redhill is focused on the development a...

3 weeks ago - Benzinga

RedHill Biopharma's Oral COVID-19 Candidate Shows Preclinical Action Against Delta Variant

RedHill Biopharma Ltd (NASDAQ: RDHL) has announced preliminary results of a new preclinical study for its COVID-19 treatment candidate, opaganib. Related:   RedHill's Novel Late-Stage Pills Hold Promise...

4 weeks ago - Benzinga

Redhill Biopharma: Q2 Earnings Insights

Shares of Redhill Biopharma (NASDAQ:RDHL) rose 11.1% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 250.00% year over year to ($0.06), which ...

4 weeks ago - Benzinga

RedHill Reports Second Quarter 2021 Results

Achieved record quarterly revenues of $21.5 million for Q2/2021, 4.5% increase from Q1/2021 despite challenging market conditions; Cash balance[1] of approximately $71.5 million as of June 30, 2021 Reco...

4 weeks ago - Accesswire

RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights

TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.

4 weeks ago - PRNewsWire

RedHill Biopharma Ltd Announces RedHill's Opaganib Strong Delta Variant Inhibition

RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant Opaganib demonstrated strong inhibition of COVID-19 Delta variant in a human bronchial epithelial cells model, addin...

4 weeks ago - Accesswire

RedHill Biopharma's Opaganib Demonstrates Strong Inhibition of COVID-19 Delta Variant

TEL AVIV, Israel and RALEIGH, N.C., Aug. 26, 2021 /PRNewswire/ -- RedHill Biopharma Ltd.

4 weeks ago - PRNewsWire

A Preview Of Redhill Biopharma's Earnings

Redhill Biopharma (NASDAQ:RDHL) will be releasing its next round of earnings this Thursday, August 26. For all of the relevant information, here is your guide for Thursday's Q2 earnings announcement.

4 weeks ago - Benzinga